No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Non-GAAP earnings in 2009 are expected to increase to $4.7/diluted share. GAAP earnings, which include amortization and stock compensation expenses, are expected to reach $3.5/diluted share. Revenue is expected to reach $5.2-5.4 bn in 2009. Genzyme is one of the world's leading biotechnology compan
are competitive and has joined up with Genencor to develop a bio-based route.
signed a 3y, $10 M extension to its collaboration with Univation for catalyst development for polyethylene technologies. Univation is a jv between Dow Chemical and ExxonMobil. Symyx also has
Ciba has forged a deal with Pure Bioscience for the marketing and development of Pure's water-soluble antimicrobial and preservative silver dihydrogen citrate for the personal care, household and industrial sectors globally. The agreement grants Ciba exclusive marketing rights to the technology in p